Noninvasive evaluation of hepatic fibrosis in hepatitis C virus-infected patients using ethoxybenzyl-magnetic resonance imaging

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 6, 2013, Pages 1032-1039

  Nojiri, Shunsuke ^a   Kusakabe, Atsunori ^a   Fujiwara, Kei ^a   Shinkai, Noboru ^a   Matsuura, Kentaro ^a   Iio, Etsuko ^a   Miyaki, Tomokatsu ^a   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

EOB MRI; Hepatic fibrosis; Noninvasive methods

Indexed keywords

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INTERVERTEBRAL DISK; LIVER; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; COMPLICATION; DIAGNOSTIC USE; LIVER CIRRHOSIS; PROCEDURES;

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOXETIC ACID;

AGED; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MALE;

EID: 84878195456     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12181     Document Type: Article

References (33)

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 2000; 132: 296-305.
2. Tsukuma H, Hiyama T, Tanaka S etal. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 1993; 328: 1797-1801.
3. Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann. Intern. Med. 1999; 131: 174-181.
4. Ikeda K, Saitoh S, Koida I etal. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
5. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996; 78: 977-985.
6. Cottone M, Turri M, Caltagirone M etal. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J. Hepatol. 1994; 21: 1029-1034.
7. Oka H, Kurioka N, Kim K etal. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12: 680-687.
8. Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 1978; 74: 103-106.
9. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann. Intern. Med. 2000; 133: 665-675.
10. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
11. Forns X, Ampurdanes S, Llovet JM etal. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992.
12. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45: 297-306.
13. Lok AS, Ghany MG, Goodman ZD etal. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42: 282-292.
14. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
15. Castera L, Vergniol J, Foucher J etal. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
16. Rouviere O, Yin M, Dresner MA etal. MR elastography of the liver: preliminary results. Radiology 2006; 240: 440-448.
17. Rizzo L, Calvaruso V, Cacopardo B etal. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am. J. Gastroenterol. 2011; 106: 2112-2120.
18. Huppertz A, Balzer T, Blakeborough A etal. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275.
19. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.
20. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183: 59-64.
21. Ryeom HK, Kim SH, Kim JY etal. Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J. Radiol. 2004; 5: 231-239.
22. Tamada T, Ito K, Higaki A etal. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur. J. Radiol. 2011; 80: e311-316.
23. Watanabe H, Kanematsu M, Goshima S etal. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminary observations. Radiology 2011; 259: 142-150.
24. Tsuda N, Okada M, Murakami T. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest. Radiol. 2007; 42: 242-247.
25. Kim T, Murakami T, Hasuike Y etal. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J. Magn. Reson. Imaging 1997; 7: 683-688.
26. Tajima T, Takao H, Akai H etal. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J. Comput. Assist. Tomogr. 2010; 34: 362-366.
27. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur. Radiol. 2008; 18: 1577-1586.
28. Motosugi U, Ichikawa T, Tominaga L etal. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur. Radiol. 2009; 19: 2623-2629.
29. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J. Pharmacol. Exp. Ther. 1999; 290: 153-157.
30. Nakai K, Tanaka H, Hanada K etal. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab. Dispos. 2008; 36: 1786-1793.
31. Ogasawara K, Terada T, Katsura T etal. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab. Pharmacokinet. 2010; 25: 190-199.
32. Hinoshita E, Taguchi K, Inokuchi A etal. Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection. J. Hepatol. 2001; 35: 765-773.
33. Tsuda N, Okada M, Murakami T. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur. J. Radiol. 2010; 73: 137-142.